Identification of molecular targets in urologic oncology

[1] Marsh S(2006)Global pharmacogenetics: giving the genome to the masses Pharmacogenomics 7 625-631

[2] Van Booven DJ(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672

[3] McLeod HL(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139

[4] Piccart-Gebhart MJ(2008)Cumulative association of five genetic variants with prostate cancer N Engl J Med 358 910-919

[5] Procter M(2006)Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification J Clin Oncol 24 5552-5564

[6] Leyland-Jones B(2007)p53 and retinoblastoma pathways in bladder cancer World J Urol 25 563-571

[7] Goldhirsch A(2004)Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma J Clin Oncol 22 975-977

[8] Untch M(2007)Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics Clin Cancer Res 13 671s-679s

[9] Smith I(2007)Renal cell carcinoma: current status and emerging therapies Cancer Treat Rev 33 299-313

[10] Gianni L(2006)Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512

[1] Marsh S(2006)Global pharmacogenetics: giving the genome to the masses Pharmacogenomics 7 625-631

[2] Van Booven DJ(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672

[3] McLeod HL(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139

[4] Piccart-Gebhart MJ(2008)Cumulative association of five genetic variants with prostate cancer N Engl J Med 358 910-919

[5] Procter M(2006)Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification J Clin Oncol 24 5552-5564

[6] Leyland-Jones B(2007)p53 and retinoblastoma pathways in bladder cancer World J Urol 25 563-571

[7] Goldhirsch A(2004)Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma J Clin Oncol 22 975-977

[8] Untch M(2007)Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics Clin Cancer Res 13 671s-679s

[9] Smith I(2007)Renal cell carcinoma: current status and emerging therapies Cancer Treat Rev 33 299-313

[10] Gianni L(2006)Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512